714 related articles for article (PubMed ID: 19414316)
1. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
2. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
Kimura H; Yamaguchi Y
Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
[TBL] [Abstract][Full Text] [Related]
3. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer.
Kobari M; Egawa S; Shibuya K; Sunamura M; Saitoh K; Matsuno S
Br J Surg; 2000 Jan; 87(1):43-8. PubMed ID: 10606909
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
Abdel-Wahab M; El-Shennawy F; Agha S; Ragab E; Fathi O; Sultan A; Elghawalby N; Ezzat F
Hepatogastroenterology; 1999 May; 46 Suppl 1():1293-6. PubMed ID: 10429977
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
[TBL] [Abstract][Full Text] [Related]
6. The role of circulating dendritic cells in patients with unresectable pancreatic cancer.
Hirooka S; Yanagimoto H; Satoi S; Yamamoto T; Toyokawa H; Yamaki S; Yui R; Inoue K; Michiura T; Kwon AH
Anticancer Res; 2011 Nov; 31(11):3827-34. PubMed ID: 22110205
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach - single center experience.
Gardini A; Morgagni P; Milandri C; Riccobon A; Ridolfi R; La Barba G; Saragoni L; Amadori D; Garcea D
Hepatogastroenterology; 2012 May; 59(115):687-90. PubMed ID: 22469709
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
10. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy.
Ohguri T; Imada H; Nomoto S; Yahara K; Hisaoka M; Hashimoto H; Tokura Y; Nakamura K; Shioyama Y; Honda H; Terashima H; Moroi Y; Furue M; Korogi Y
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1446-53. PubMed ID: 15817349
[TBL] [Abstract][Full Text] [Related]
11. EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer.
Yamamoto K; Shimada S; Hirota M; Yagi Y; Matsuda M; Baba H
Int J Oncol; 2005 Nov; 27(5):1321-8. PubMed ID: 16211228
[TBL] [Abstract][Full Text] [Related]
12. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
14. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome.
Brouquet A; Goéré D; Lefèvre JH; Bonnet S; Dumont F; Raynard B; Elias D
Ann Surg Oncol; 2009 Oct; 16(10):2744-51. PubMed ID: 19626375
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic hepatic irradiation following curative resection of pancreatic cancer.
Hishinuma S; Ogata Y; Tomikawa M; Ozawa I; Inoue K; Katano S; Tsukiyama I
J Hepatobiliary Pancreat Surg; 2005; 12(3):235-42. PubMed ID: 15995813
[TBL] [Abstract][Full Text] [Related]
16. [Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer].
Toh U; Fujii T; Mishima M; Imaizumi T; Koga A; Yano S; Shirouzu K; Yahara T; Yamana H
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1931-3. PubMed ID: 18219856
[TBL] [Abstract][Full Text] [Related]
17. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
Morisaki T; Matsumoto K; Kuroki H; Kubo M; Baba E; Onishi H; Tasaki A; Nakamura M; Inaba S; Katano M
Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
[TBL] [Abstract][Full Text] [Related]
18. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
[TBL] [Abstract][Full Text] [Related]
19. [Combination of adoptive immunotherapy and chemotherapy against advanced cancer with peritoneal dissemination].
Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Tamai M; Taniguchi K; Aoki Y
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1558-64. PubMed ID: 2172423
[TBL] [Abstract][Full Text] [Related]
20. Unresectable pancreatic cancer: is a multi-modality approach a promising therapeutical alternative?
Lygidakis NJ; Dedemati G; Spenzaris N; Theodoropoulou M
Hepatogastroenterology; 1997; 44(16):1222-8. PubMed ID: 9261631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
